Long-term metformin usage and cognitive function among older adults with diabetes

Journal of Alzheimer's Disease

Volumn 41, Issue 1, 2014, Pages 61-68

  Ng, Tze Pin ^a,b   Feng, Liang ^a,b   Yap, Keng Bee ^a,c   Lee, Tih Shih ^a,d   Tan, Chay Hoon ^a,b   Winblad, Bengt ^e  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c ALEXANDRA HOSPITAL   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cognition; dementia; diabetes; insulin resistance; metformin

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON 4; METFORMIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; COGNITIVE DEFECT; DEPRESSION; DIABETES MELLITUS; DIET RESTRICTION; DNA POLYMORPHISM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RISK REDUCTION; SINGAPORE; VERY ELDERLY; COGNITION DISORDERS; CROSS-SECTIONAL STUDY; LONGITUDINAL STUDY; MULTIVARIATE ANALYSIS; ODDS RATIO; PROSPECTIVE STUDY; STATISTICAL MODEL; TIME FACTOR;

AGED; AGED, 80 AND OVER; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; METFORMIN; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROSPECTIVE STUDIES; SINGAPORE; TIME FACTORS;

EID: 84902239478     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131901     Document Type: Article

References (37)

1. Cukierman T, Gerstein HC, Williamson JD (2005) Cognitive decline and dementia in diabetes-a systematic overview of prospective observational studies. Diabetologia 48, 2460-2469.
2. Peila R, Rodriguez BL, Launer LJ, Honolulu-Asia AS (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51, 1256-1262.
3. Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K (2004) Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 63, 658-663.
4. Cukierman-Yaffe T, Gerstein HC, Williamson JD, Lazar RM, Lovato L, Miller ME, Coker LH, Murray A, Sullivan MD, Marcovina SM, Launer LJ, Action to Control Cardiovascular Riskin Diabetes-Memoryin Diabetes (ACCORD-MIND), Investigators (2009) Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: The action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care 32, 221-226.
5. Abbatecola AM, Paolisso G, Lamponi M, Bandinelli S, Lau-retani F, Launer L, Ferrucci L (2004) Insulin resistance and executive dysfunction in older persons. J Am Geriatr Soc 52, 1713-1718.
6. Vanhanen M, Koivisto K, Kuusisto J, Mykkänen L, Hel-kala EL, Hänninen T, Riekkinen P Sr, Soininen H, Laakso M (1998) Cognitive function in an elderly population with persistent impaired glucose tolerance. Diabetes Care 21, 398-402.
7. Biessels GJ (1999) Cerebral complications of diabetes: Clinical findings and pathogenic mechanisms. Neth J Med 54, 34-45.
8. Craft S (2005) Insulin resistance syndrome and Alzheimer's disease: Age-and obesity-related effects on mem-ory, amyloid, and inflammation. Neurobiol Aging 26, 65-69.
9. Kalmijn S, Feskens EJ, Launer LJ, Stijnen T, Kromhout D (1995) Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia 38, 1096-1102.
10. Geroldi C, Frisoni GB, Paolisso G, Bandinelli S, Lamponi M, Abbatecola AM, Zanetti O, Guralnik JM, Ferrucci L (2005) Insulin resistance in cognitive impairment: The InCHIANTI study. Arch Neurol 62, 1067-1072.
11. Wakisaka M, Nagamachi S, Inoue K, Morotomi Y, Nunoi K, Fujishima M (1990) Reduced regional cerebral blood flow in aged noninsulin-dependent diabetic patients with no history of cerebrovascular disease: Evaluation by N-isopropyl-123Ip-iodoamphetamine with single-photon emission computed tomography. J Diabetes Complications 4, 170-174.
12. Convit A (2005) Links between cognitive impairment in insulin resistance: An explanatory model. Neurobiol Aging 26, 31-35.
13. Messier C, Gagnon M (1996) Glucose regulation and cognitive functions: Relation to Alzheimer's disease and diabetes. Behav Brain Res 75, 1-11.
14. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid fj-protein, and the fj-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 100, 4162-4167.
15. Selkoe DJ (2000) The origins of Alzheimer disease: A is for amyloid. JAMA 283, 1615-1617.
16. Pathan AR, Gaikwad AB, Viswanad B, Ramarao P (2008) Rosiglitazone attenuates the cognitive deficits induced by high fat diet feeding in rats. Eur J Pharmacol 589, 176-179.
17. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: A preliminary study. Am J Geriatr Psychiatry 13, 950-958.
18. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD, Rosiglitazone in Alzheimer's Disease Study, Group (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacoge-nomics J 6, 246-254.
19. Abbatecola AM, Lattanzio F, Molinari AM, Cioffi M, Mansi L, Rambaldi P, DiCioccio L, Cacciapuoti F, Canonico R, Paolisso G (2010) Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment. Diabetes Care 33, 1706-1711.
20. Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnamagi U, Sawchak S (2010) Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: Results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 30, 131-146.
21. Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM, Irizarry M, Jeter B, Zvartau-Hind M, van Dyck CH, Gold M (2011) Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: Two Phase 3 studies. Curr Alzheimer Res 8, 592-606.
22. U. S. Food and Drug Administration (2010) FDA Drug Safety Communication: Ongoing review of Avandia (rosiglitazone) and cardiovascular safety. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafe tyInformationforPatientsandProviders/ucm201418.htm
23. Rasgon NL, Kenna HA (2005) Insulin resistanceindepressive disorders and Alzheimer's disease: Revisiting the missing link hypothesis. Neurobiol Aging 26, 103-107.
24. Niti M, Yap KB, Kua EH, Tan CH, Ng TP (2008) Physical, social and productive leisure activities, cognitive decline and interaction with APOE-epsilon 4 genotype in Chinese older adults. Int Psychogeriatr 20, 237-251.
25. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. J Psychiatr Res 12, 189-198.
26. Ng TP, Niti M, Chiam PC, Kua EH (2007) Ethnic and educational differences in cognitive test performance on mini-mental state examination in Asians. Am J Geriatr Psychiatry 15, 130-139.
27. Yesavage J (1988) Geriatric Depression Scale. Psychophar-macol Bull 24, 709-711.
28. Nyunt MS, Fones C, Niti M, Ng TP (2009) Criterion-based validity and reliability of the Geriatric Depression Screening Scale (GDS-15) in a large validation sample of community-living Asian older adults. Aging Ment Health 13, 376-382.
29. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130, 461-470.
30. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108, 1167-1174.
31. Kirpichnikov D, McFarlane SI, Sowers JR (2002) Metformin: An update. Ann Intern Med 137, 25-33.
32. Mamputu JC, Wiernsperger NF, Renier G (2003) Antiathero-genic properties of metformin: The experimental evidence. Diabetes Metab 29, 6S71-6S76.
33. Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, Schönbeck U, Libby P (2006) Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol 26, 611-617.
34. Wilcock C, Bailey CJ (1994) Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 24, 49-57.
35. El-Mir MY, Detaille D, R-Villanueva G, Delgado-Esteban M, Guigas B, Attia S, Fontaine E, Almeida A, Leverve X (2008) Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons. J Mol Neurosci 34, 77-87.
36. Łabuzek K, Liber S, Gabryel B, Okopieñ B (2010) Metformin has adenosine-monophosphate activated protein kinase (AMPK)-independent effects on LPS-stimulated rat primary microglial cultures. Pharmacol Rep 62, 827-848.
37. Yaffe K, Falvey C, Hamilton N, Schwartz AV, Simonsick EM, Satterfield S, Cauley JA, Rosano C, Launer LJ, Strotmeyer ES, Harris TB (2012) Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia. Arch Neurol 69, 1170-1175.